Product logins

Find logins to all Clarivate products below.

home   •  Research Reports  •  DRG Market Assessment Reports

Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia | Emerging Therapies | Venclexta (venetoclax) | US | Wave 3 | 2017

Login to access report north_east
Contact sales account_box

Venclexta (Wave 3) is the third in a multiwave series designed to track physician perception and uptake of as well as the competitive environment for the newly launched chronic lymphocytic leukemia (CLL) drug Venclexta (Roche/Genentech’s venetoclax). Launch Tracking Venclexta measures the impact of this novel agent on the relapsed/refractory CLL with del(17p) therapy market following launch, based on a blend of quantitative and qualitative primary research with U.S. hematologist-oncologists. This content evaluates physicians’ current awareness and perception of Venclexta relative to other currently available therapies for relapsed/refractory CLL, current and anticipated use of Venclexta, and promotional activity for Venclexta.

What you will learn in this content:

  • What is U.S. hematologist-oncologists’ awareness of and familiarity with Venclexta, and what are their perceptions of this product?
  • Among prescribers, for which patients are they prescribing Venclexta, what are the reasons for prescribing, and how satisfied are they with Venclexta?
  • What promotional messages and activities are Roche/Genentech employing in support of the Venclexta launch?
  • How do prescribers and nonprescribers compare across key metrics?
  • How is the trial and adoption of Venclexta tracking compared with other recent first-in-class product launches in the oncology market?

Methodology: ~75-100 U.S. hematologist-oncologists complete a 30-minute online quantitative survey with several open-ended questions for qualitative feedback. In addition, ten surveyed specialists participate in a 30-minute follow-up qualitative interview.

Related reports: Venclexta Launch Tracking (US) Wave 1, Venclexta Launch Tracking (US) Wave 2, Derzalex/Emplicity Launch Tracking (US) Wave 3

Contact sales account_box
Login to access report north_east

Related Market Assessment Reports

Report
Multiple Sclerosis – Current Treatment – Treatment Algorithms: Claims Data Analysis – Multiple Sclerosis (US)
The multiple sclerosis (MS) therapy market comprises more than 20 immunomodulatory disease-modifying therapies (DMTs), and more are in the pipeline. A variety of drug classes each hold a niche…
north_east
Report
Asthma – Access & Reimbursement – Access & Reimbursement – Asthma (US)
The dynamics within the LABA/ICS FDC, LAMA, LABA/LAMA/ICS FDC, and biological drug classes will continue to shape the U.S. asthma market. The dominance of branded LABA/ICS FDCs (e.g., GSK’s…
north_east
Report
Systemic Lupus Erythematosus – Access & Reimbursement – Access & Reimbursement – Systemic Lupus Erythematosus (US)
The U.S. systemic lupus erythematosus (SLE) therapy market is largely genericized and off-label. With the exception of GSK’s Benlysta, the firstagents approved for the indication in almost 60…
north_east
Report
Membranous Nephropathy – Landscape & Forecast – Disease Landscape & Forecast (G7)
Primary membranous nephropathy (pMN), the most common type of MN, is a rare autoantibody-mediated autoimmune kidney disease. Although it is one of the leading causes of nephrotic syndrome in…
north_east
Report
Heart Failure – Current Treatment – Treatment Algorithms: Claims Data Analysis – Heart Failure with Reduced Ejection Fraction (US)
Heart failure with reduced ejection fraction (HFrEF) occurs when the left ventricular ejection fraction (LVEF) is 40% or less. Drug treatment for HFrEF is well established and supported by…
north_east

Follow us

Contact us

Sales enquiries north_east
Customer service north_east
Support north_east